KCT0001243尚未招募未知
A randomized, open-label, multiple dosing, 2-way crossover study to evaluate the pharmacokinetic effect of tamsulosin on tadalafil in healthy male volunteers
Chong Kun Dang0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- Male
入选标准
- •1. Healthy man age 19 years or more and less than 55 years old at the time of screening.
- •2. Body mass index(BMI) more than 17.5kg / m2 and less than 30.5kg / m2 and weight more than 55kg
- •3. Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.
- •4. Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as electrocardiography(ECG) test.
- •5. Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital Institutional Review Board(IRB).
- •6. Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.
排除标准
- •1. Subject who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)
- •2. Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
- •3. Showing the value that corresponds to following laboratory parameters : AST(aspartate transaminase) or ALT(alanine transaminase) > 2* upper limit of normal range.
- •4. Alcohol > 210g/week, within 6 months prior to the screening.
- •5. Taking the medication involved in other clinical trials within two months before the first dose medication characters.
- •6. Sitting Systolic Blood Pressure = 140 mmHg, Diastolic Blood Pressure = 90 mmHg at the time of screening.
- •7. History of alcohol or drug abuse, within 1 year
- •8. Positive result in urine drug test(Amphetamines, Cocaine, Opioid, Benzodiazepines, Cannabinoid)
- •9. Positive result in Serology test(Hepatitis B, Hepatitis C, HIV(Human Immunodeficiency Virus), TPPA(qual)).
- •10. Subject who takes an abnormal meal which can affect the ADME(Absorption, Distribution, Metabolism, Excretion) of drug.
- •11. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
- •12. Smoker (= 20cigarettes/day)
- •13. Subjects who takes ethical the count(ETC) or over the count
- •(OTC) medicine within 10days before the first investigational product(IP) administration.
- •14. Subject who done the whole blood donation within two months or component blood donation within 1 month prior to the first dosing.
- •15. Subject who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
- •16. Subject with taking any forms of organic nitrate periodically and/or intermittently.
- •17. Subject with known hereditary degenerative retinal disease including retinitis pigmentosa.
- •18. Subject with serious history of hypersensitivity or allergy to investigational product.
- •19. Subject who Lost sight of one eye by Non-arteritic anterior ischemic optic neuropathy (NAION).
- •20. Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption.
- •21. Orthostatic hypotension
- •22. Subjects who is not able to comply with guidelines described in the protocol.
- •23. Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.
研究者
相似试验
尚未招募
不适用
Study to investigate the effect of tadalafil the pharmacokinetic properties of tamsulosinon after oral administration in healthy male volunteersDiseases of The genitoruinary systemKCT0001245Chong Kun Dang28
尚未招募
1 期
A randomized, open-labeled, multiple-dose, two-way crossover design with two-period, two-treatment, two-sequence steady-state bioequivalence study of Venlafaxine Hydrochloride Extended-Release Capsules 150 mg and Efexor XR 150 mg Capsules in healthy, adult, Thai volunteers under fed conditioHealthy subjectsBioequivalence Venlafaxine Hydrochloride Extended-Release Capsules 150 mgTCTR20240706012Bio-innova Co., Ltd.44
已完成
不适用
An open-label, multiple dose, randomized, two-way crossover study to evaluate the effects of BGG492 on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteersEpilepsieEpilepsiafalling diseaseNL-OMON34415ovartis24
进行中（未招募）
不适用
The purpose of this study is to evaluate the pharmacokinetic interaction between Atorvastatin and Fenofibric acidDiseases of the circulatory systemKCT0001438Chong Kun Dang30
已完成
不适用
Clinical study to evaluate pharmacokinetic drug-drug interaction and safety between nebivolol and rosuvastatiDiseases of the circulatory systemKCT0001794Elyson Pharmaceutical44